Ostarine (MK-2866) and LGD-4033 (Ligandrol) are two selective androgen receptor modulators (SARMs) that have attracted considerable scientific interest for their effects on skeletal muscle.
Both compounds have demonstrated encouraging increases in lean body mass during controlled human clinical investigations.
What makes this comparison particularly interesting is that both have produced measurable results, despite being investigated in different populations and over different study periods.
Ostarine: Encouraging Human Muscle Research
Ostarine, also known as Enobosarm, has been extensively investigated for its potential influence on lean body mass and physical function.
A landmark 2011 Phase II clinical trial examined 120 older men and postmenopausal women over 12 weeks.
At the highest investigated dose, researchers reported an average 1.25 kg increase in lean body mass, significantly greater than the change observed with placebo.
The investigation also demonstrated statistically significant improvements in stair-climb power, providing evidence of changes in both lean tissue and a measure of physical performance.
These findings helped establish Ostarine as an important subject of clinical muscle research.
Read the 2011 Ostarine clinical investigation.
LGD-4033: Measurable Changes in Just Three Weeks
LGD-4033 has demonstrated similarly interesting activity in human research, particularly during a comparatively short experimental period.
A 2013 randomised, placebo-controlled study investigated LGD-4033 in 76 healthy men over 21 days.
Researchers observed dose-dependent increases in lean body mass, with an average 1.21 kg increase at the highest investigated dose, significantly greater than placebo.
This was a particularly noteworthy finding given the short duration of the investigation.
Although muscle strength did not improve significantly compared with placebo, the study demonstrated measurable changes in body composition within three weeks.
Read the 2013 LGD-4033 clinical investigation.
How Do Their Clinical Findings Compare?
| Research characteristic | Ostarine | LGD-4033 |
|---|---|---|
| Human trial participants | 120 older adults | 76 healthy men |
| Study duration | 12 weeks | 21 days |
| Lean body mass increase | Approximately 1.25 kg | Approximately 1.21 kg |
| Physical-function improvements | Demonstrated | Not established |
| Human anabolic activity | Demonstrated | Demonstrated |
The lean-mass figures represent changes within the respective experimental groups, not results from a direct comparison.
Both compounds demonstrated measurable anabolic activity, but their findings cannot establish which is more effective.
Differences in participant characteristics, study duration and experimental conditions prevent reliable conclusions about relative potency.
What About Muscle Retention?
Although both compounds increased lean body mass in human investigations, neither trial directly established superiority for preserving muscle during calorie restriction.
Muscle retention and increases in lean body mass are related but distinct research outcomes.
Nevertheless, the findings provide a meaningful scientific foundation for continued investigation into selective androgen receptor activity and skeletal muscle.
For broader information about these mechanisms, visit our Complete SARMs Research Guide.
Final Thoughts
Ostarine and LGD-4033 have both produced impressive findings in controlled human research.
Ostarine demonstrated improvements in lean body mass and certain physical-function measurements over 12 weeks, while LGD-4033 produced measurable lean-mass increases within just 21 days.
These findings highlight the significant research interest surrounding both compounds, with each demonstrating distinct characteristics worthy of further clinical investigation.
Direct comparative trials would be required to establish whether either offers advantages for muscle retention.
Research Use Only: Ostarine and LGD-4033 are investigational compounds not approved for human consumption as sports supplements. Their safety and effectiveness for bodybuilding or muscle preservation in healthy individuals have not been established.
